{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069211","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.922975+00:00","generated_at":"2026-05-21T23:39:22.172027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"REGENXBIO Q1 net income $6.1M; revenue up 471% to $89M on Nippon Shinyaku deal","bullets":["Net income $6.1M ($0.12 EPS) vs net loss $63.3M ($1.38 loss) in Q1 2024.","Revenue $89.0M (vs $15.6M) driven by $71.8M license revenue from Nippon Shinyaku partnership.","Cash $272.7M; operations funded into 2H 2026; guidance excludes milestone payments and PRV.","RGX-202 Duchenne pivotal trial >50% enrolled; BLA submission on track for mid-2026.","FDA expected to accept BLA for clemidsogene lanparvovec (RGX-121) in May; potential 2025 approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069211","json":"https://secwatch.observer/filing/0000950170-25-069211.json","markdown":"https://secwatch.observer/filing/0000950170-25-069211.md","text":"https://secwatch.observer/filing/0000950170-25-069211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017025069211/0000950170-25-069211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017025069211/rgnx-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:39:22.172027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}